文献速递慢性肾脏病血液净化与透析肾血管病与高血压

2型糖尿病合并CKD患者减重干预的心肾结局

Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

这项回顾性队列研究利用TriNetX美国协作网络数据,评估司美格鲁肽、替尔泊肽和减重手术对2型糖尿病合并CKD超重或肥胖患者心肾结局及死亡率的影响。与DPP4i对照组相比,三种干预均降低ESRD、心梗、卒中和全因死亡风险,支持其作为疾病修饰治疗选择。

要点

  • 司美格鲁肽、替尔泊肽和减重手术均降低ESRD风险(HR分别为0.78、0.58、0.79)。
  • 三种干预均降低心梗、卒中和全因死亡风险。
  • 结果支持将减重干预作为T2DM合并CKD的疾病修饰治疗。

核心结论

  • 在2型糖尿病合并CKD超重或肥胖患者中,司美格鲁肽、替尔泊肽和减重手术对心肾结局和死亡率有多重获益。

研究设计与样本

  • 回顾性队列研究,使用TriNetX美国协作网络健康记录,将三种干预队列与DPP4i对照组进行倾向性评分匹配。

主要发现

  • 与DPP4i相比,司美格鲁肽降低ESRD风险(HR 0.78,95%CI 0.71-0.85),替尔泊肽降低42%(HR 0.58,95%CI 0.45-0.75),减重手术降低ESRD风险(HR 0.79,95%CI 0.67-0.92)。
  • 司美格鲁肽降低心梗(HR 0.80,95%CI 0.72-0.88)和卒中(HR 0.85,95%CI 0.77-0.95)风险;替尔泊肽降低心梗和卒中风险24%。
  • 减重手术降低心梗(HR 0.45,95%CI 0.35-0.58)和卒中(HR 0.57,95%CI 0.44-0.74)风险。
  • 全因死亡风险降低:司美格鲁肽(HR 0.64,95%CI 0.59-0.70)、替尔泊肽(HR 0.47,95%CI 0.35-0.63)、减重手术(HR 0.68,95%CI 0.57-0.81)。

临床怎么用

  • 对于2型糖尿病合并CKD的超重或肥胖患者,可考虑使用司美格鲁肽、替尔泊肽或减重手术以改善心肾结局和降低死亡率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: In patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), there remains a paucity of data from large, high-quality, real-world studies on the efficacy of weight-lowering interventions, including the glucagon-like peptide-1-based therapies semaglutide and tirzepatide, as well as bariatric surgery (BS). This retrospective cohort study evaluates these interventions on cardiorenal outcomes and mortality using health records from TriNetX US Collaborative Network. METHODS: Three cohorts with T2DM and CKD living with overweight or obesity, prescribed semaglutide or tirzepatide, or with a BS procedure were propensity-score matched with a cohort receiving dipeptidyl peptidase 4 inhibitors (DPP4i, weight-neutral control). We investigated the hazard ratio (HR) of: (i) end-stage renal disease (ESRD); (ii) myocardial infarction (MI); (iii) stroke; and (iv) all-cause mortality. RESULTS: Cohorts included 17 749 (semaglutide, age 64.1 ± 10.9 years, 57.4% female), 4211 (tirzepatide, 63.7 ± 10.8, 58.1%) and 2603 (BS, 56.1 ± 11.2, 74.1%) patients. Compared with DPP4i, semaglutide reduced the risk of ESRD [HR 0.78 (95% confidence interval 0.71 to 0.85)], while tirzepatide showed a reduction of 42% (0.0.58, 0.45 to 0.75). BS lowered ESRD risk (0.79, 0.67 to 0.92). Semaglutide reduced MI (0.80, 0.72 to 0.88) and stroke (0.85, 0.77 to 0.95) risk, while tirzepatide lowered MI and stroke by 24%. BS was associated with reduced MI (0.45, 0.35 to 0.58) and stroke (0.57, 0.44 to 0.74) risk. All-cause mortality risk was reduced by semaglutide (0.64, 0.59 to 0.70), tirzepatide (0.47, 0.35 to 0.63) and BS (0.68, 0.57 to 0.81). CONCLUSIONS: Using a real-world dataset, semaglutide, tirzepatide and BS-interventions shown to elicit weight loss and improve glycaemic control-have a myriad of benefits on cardio-renal outcomes and mortality, supporting their use as disease-modifying therapy options in T2DM and CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Wilkinson TJ, Goldney J, Yates T, et al. Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes. Nephrol Dial Transplant. 2026. PMID: 41344888. doi:10.1093/ndt/gfaf258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。